Systemic immune-inflammation index and other inflammatory parameters in patients receiving biological or targeted synthetic DMARDs for inflammatory rheumatic disease

Abstract

Objective: To investigate the short – and long-term dynamics in inflammation markers [systemic immune-inflammation index (SII),
 neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/ monocyte ratio (LMR)] before and after
 biological disease-modifying antirheumatic drugs (bDMARD) or targeted synthetic DMARD (tsDMARD) treatment.
 Patients and Methods: wo hundred twenty-six patients (115 women, 47±13.8 years) were included. Age, gender, disease duration, and
 treatments were recorded retrospectively. Complete blood counts including neutrophil, lymphocyte, platelet, monocyte and acute
 phase reactants were noted at the visit before the biological treatment, at the 3rd month, 6th month, and the last visit on medication.
 SII, NLR, PLR and LMR were calculated, and their dynamics over time were compared.
 Results: Significant changes were observed over time in all parameters reflecting inflammation (SII, NLR, PLR, LMR, ESR, and CRP)
 (p

Evaluating the Diagnostic Performance of Systemic Immune-Inflammation Index in Childhood Inflammatory Arthritis: A Focus on Differentiating Juvenile Idiopathic Arthritis from Reactive Arthritis

“…The elevated platelet count in children with JIA compared to those with Reactive Arthritis may reflect the intensity and chronic nature of the inflammatory response associated with JIA [77]. Inflammatory conditions, such as JIA, can stimulate platelet production in the bone marrow and alter their lifespan, leading to an increase in circulating platelet levels [74,78]. The inflammatory milieu in JIA involves various immune cells and cytokines that contribute to the activation of platelets [46].…”